Undifferentiated Ovarian Carcinoma Completed Phase 2 Trials for Paclitaxel (DB01229)

IndicationStatusPhase
DBCOND0028876 (Undifferentiated Ovarian Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00888615Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerTreatment